Atopic dermatitis drug risks
The risks of atopic dermatitis drugs will be the topic of an Oct. 29-30 meeting of the Pediatric Subcommittee of FDA's Anti-Infective Drugs Advisory Committee. On Oct. 29, the committee will discuss the risks of hypothalamic-pituitary axis suppression in children being treated for atopic dermatitis. The committee will also hear reports on adverse events with Pfizer's Zyrtec and Accupril; Merck's Cozaar; AstraZeneca's Nolvadex, Orphan Medical's Busulfex and Bristol-Myers Squibb's Serzone. On Oct. 30, the committee will discuss long-term monitoring of cancer recurrence in atopic dermatitis patients who are being treated with immunosuppressants. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m...
You may also be interested in...
The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.
Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.